Discovery and Early Clinical Development of CLN-081 (TAS6417) in NSCLC with EGFR Exon 20 Insertion Mutations

Time: 11:30 am
day: Day One

Details:

  • Challenges in the discovery of an Ex20 targeted therapy
  • Preclinical characterization of CLN-081 in models of Ex20 NSCLC
  • Safety and early signs of efficacy in patients with Ex20 NSCLC

Speakers: